Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03283696 · ClinicalTrials.gov registry record · Phase 1
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
A Phase 1 study of Soft Tissue Sarcoma, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 6
- Study locations
NCT03283696 is a Phase 1 study of Soft Tissue Sarcoma that has completed, run by Eli Lilly and Company. The registered enrollment target is 24 participants, below the 79-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (70% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT03283696, a Phase 1 study of Soft Tissue Sarcoma, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to evaluate the safety of ifosfamide when added to the combination regimen of olaratumab and doxorubicin in participants with advanced or metastatic soft tissue sarcoma (STS).
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG Mesna
- DRUG Ifosfamide
- DRUG Olaratumab
Study Locations (6)
Other
- HELIOS Klinikum Berlin-Buch - Berlin
- Università degli Studi di Catania - Azienda Policlinico - Catania
Florida
- University of Miami School of Medicine - Miami
Texas
- University of Texas MD Anderson Cancer Center - Houston
North Rhine-Westphalia
- Universitätsklinikum Essen - Essen
Lombardy
- Istituto Nazionale dei Tumori - Milan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-10-18 |
| Est. Completion | 2019-08-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03283696
The ClinicalTrials.gov registry entry for NCT03283696 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 79-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (70% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 4 interventions - of which Doxorubicin is the first listed.
NCT03283696 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT03283696 about?
NCT03283696 is a clinical study titled "A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma". The purpose of this study is to evaluate the safety of ifosfamide when added to the combination regimen of olaratumab and doxorubicin in participants with advanced or metastatic soft tissue sarcoma (STS).
What is the current status of trial NCT03283696?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-10-18. Estimated completion is 2019-08-25.
What conditions does trial NCT03283696 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma.
What interventions are being tested in trial NCT03283696?
The interventions under investigation include: Doxorubicin (DRUG), Mesna (DRUG), Ifosfamide (DRUG), Olaratumab (DRUG).
Who is sponsoring clinical trial NCT03283696?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03283696 being conducted?
This trial has 6 study locations across Florida, Texas, North Rhine-Westphalia, Lombardy. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
-
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
RECRUITING · Phase 1
-
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.